Bullboard - Stock Discussion Forum Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Add To Watchlist

NDAQ:LMNL - Post Discussion

Liminal BioSciences Inc. > What will the new "Ryplazim partnership" include?

View:

Post by stockman6767 on Nov 21, 2019 12:10pm

What will the new "Ryplazim partnership" include?

I am not that clear on what the new "Ryplazim partnership" would include. I have 3 possibilities in mind, 1) it only includes the rights to what will be included under the current expected FDA approval in H1 - Ryplazim™ for the only current indication for treatment of PLGD, or 2) It will also include all rights to all future developments and indications to be treated by Ryplazim for any indication yet to be developed, or 3) this is but a short form terminology that really includes all future protein therapeutics for all plasma derived therapeutics? Until now my understanding has been 1) but I have never really been clear on this. If in fact it is 1), then there will not be very big dollars on the partnership announcement. Anyone have any clarity on this?

153